fashion -WSS

fashion

author：Wikipedia 2025-09-27 10:02:32 - browse：5622

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Radiation, mainstay of cancer treatment, begins a fade

Wikipedia

WSS

Takeda, Janssen join wearable maker to measure scratching

With clinical trial data readouts, here's how to spot spin

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Diversity in medical illustrations gets boost from Chidiebere Ibe

Feds fine Medicare Advantage plans for overcharging members

Neuroscience startup Neumora files for IPO

leisure time

fashion

Wikipedia

In Memoriam: Notable people who died in 2023

ReNAgade cuts staff seven months after raising $300 million

After affirmative action ruling, medical educators look to 'holistic review'

Despite FDA concern, risk that CAR

Medical records are filled with copy

How to make AI work for medicine

Peter Hotez and the public health issue of online harassment

How to make AI work for medicine

Medical records are filled with copy

The EPA's new lead rule: How one expert crunched the numbers

hotspot

AstraZeneca bets AAV gene therapy will still deliver the goods

How a symptom of dementia informs our understanding of creativity

Flagship Pioneering launches a new biotech in two countries

Fetal surgery at risk from Dobbs and new abortion restrictions

How to make AI work for medicine

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

focus

leisure time

focus

leisure time